Sensus Healthcare Receives Medical Device License from Health Canada
November 15, 2012
Boca Raton, FL
Sensus Healthcare is proud to announce that it has received a Medical Device License from Health Canada, permitting the company to commence selling its advanced SRT-100™ in Canada. The SRT-100™ is a state-of-the-art therapy device for Non-Melanoma Skin Cancer. The SRT-100™ provides patients with a virtually pain-free, non-invasive treatment option, while achieving excellent clinical outcomes that are comparable to surgery, and without scarring. Sensus Healthcare has reintroduced superficial radiotherapy (SRT) to the global clinical community as a viable, safe, and cost-effective modality to treat non-melanoma skin cancers in hospitals and private practice settings.
“We are thrilled to have gained the Medical Device License from Health Canada and enter the Canadian market, which is one of the leading and most advanced healthcare markets in the world. We have a long legacy and strong ties with Canada’s healthcare professionals, research institutions, and patient care philosophy. We are looking forward to sell and install our SRT-100™ system throughout Canada and forming long-lasting relationships with the leading luminary institutions there, the medical care providers, and the patient community for many years to come!” stated Joe Sardano, President/CEO, Sensus Healthcare.
SRT-100™ is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam™ characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100™ is FDA, CE, Health Canada, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards. About Sensus Healthcare: Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. Media Contact: Michelle Verina Public Relations 561-922-5808 Ext. 100 firstname.lastname@example.org
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
- 95%+ cure rates that rival surgery
- No anesthesia, cutting, bleeding, stitching or pain
- No downtime or lifestyle restrictions
- Super cosmesis, no unsightly scarring
- No need for post-treatment reconstructive surgeries